ReviewMolecular diversity2026
Recent progress in the development of HSP90 inhibitors: structure-activity relationship and biological evaluation studies.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structural analysis ofbioRxiv : the preprint server for biology · 2026Article
- Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cellular biology, Heat Shock Protein 90 (Hsp90) plays a pivotal role in coordinating several processes essential or cellular survival, cell signaling and other processes. This analysis explores the complex structure, biological significance, and regulatory mechanisms clarifying its essential function in preserving cellular homeostasis and its relevance in a range of illnesses, such as cancer, neurological conditions, infectious diseases, cardiovascular conditions, and autoimmune diseases. Hsp90 is a prominent target for cancer treatment. The current manuscript involved the recent progress in the synthesis and development of Hsp90 inhibitor for the treatment of cancer. In this manuscript, the authors have compiled the Hsp90 inhibitors containing various heterocyclic rings such as Benzothiazone, Benzamide, Isoxazole, Pyrimidinone, Imidazole, Pyrimidine, Isatin, Quinazoline and Pyrazole etc. In this review, the authors incorporate the anticancer activity, Structure-Activity Relationship (SAR), Molecular Docking studies and Biological Evaluation of recently synthesized Hsp90 inhibitors. The authors have also added the clinical trial status of Hsp90 inhibitors and their potential use in cancer therapy. Overall, this review highlights the recent advancements in the field of Hsp90 inhibitor from 2020 to present. This review provides medicinal chemists with comprehensive insights into the development of Hsp90 inhibitors by guiding future research and drug discovery efforts in cancer.
Indexed as
Identifiers
40767890What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.